Xiao-Long Fu

List of Publications by Year
in descending order

97 papers	1,527 citations	394421 19 h-index	414414 32 g-index
103 all docs	103 docs citations	103 times ranked	2034 citing authors

#	Article	IF	Citations
1	Dosimetric effect of intensity-modulated radiation therapy for postoperative non-small cell lung cancer with and without air cavity in the planning target volume. Medical Dosimetry, 2022, 47, 32-37.	0.9	0
2	Radiosensitivity-Specific Proteomic and Signaling Pathway Network of Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2022, 112, 529-541.	0.8	8
3	Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer. BMC Cancer, 2022, 22, 96.	2.6	2
4	Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors. Medical Oncology, 2022, 39, 25.	2.5	2
5	Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma. Cancer Management and Research, 2022, Volume 14, 1293-1302.	1.9	0
6	Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. , 2022, 10, e004291.		77
7	A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. Radiotherapy and Oncology, 2022, 173, 313-318.	0.6	2
8	Intensity Modulated Radiation Therapy for Pleural Recurrence of Thymoma: A Prospective Phase 2 Study. International Journal of Radiation Oncology Biology Physics, 2021, 109, 775-782.	0.8	4
9	Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1349-1358.	0.8	35
10	A Novel Anticancer Therapeutic Strategy to Target Autophagy Accelerates Radiation-Associated Atherosclerosis. International Journal of Radiation Oncology Biology Physics, 2021, 109, 540-552.	0.8	6
11	Evaluation of IGRT-Induced Imaging Doses and Secondary Cancer Risk for SBRT Early Lung Cancer Patients In Silico Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110164.	1.9	1
12	Deep learning-based automatic delineation of the hippocampus by MRI: geometric and dosimetric evaluation. Radiation Oncology, 2021, 16, 12.	2.7	7
13	Clinical impact of the tumor immune microenvironment in completely resected stage IIIA(N2) non-small cell lung cancer based on an immunological score approach. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098497.	3.2	14
14	Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability. Technology in Cancer Research and Treatment, 2021, 20, 153303382110119.	1.9	1
15	KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncology, 2021, 17, 1143-1153.	2.4	63
16	A novel specific grading standard study of auto-segmentation of organs at risk in thorax: subjective–objective-combined grading standard. BioMedical Engineering OnLine, 2021, 20, 54.	2.7	2
17	Adjuvant chemotherapy improves survival outcomes after complete resection of thymic squamous cell carcinoma: a retrospective study of 116 patients. Interactive Cardiovascular and Thoracic Surgery, 2021, 33, 550-556.	1.1	2
18	Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics. Journal of Gastrointestinal Oncology, 2021, 12, 991-1006.	1.4	0

#	Article	IF	Citations
19	Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non–small cell lung cancer: A real-world validation study. Lung Cancer, 2021, 156, 100-108.	2.0	6
20	Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma. Radiotherapy and Oncology, 2021, 159, 190-196.	0.6	3
21	The Plasma Levels and Polymorphisms of Vitronectin Predict Radiation Pneumonitis in Patients With Lung Cancer Receiving Thoracic Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 757-765.	0.8	2
22	Predicting Malignancy and Invasiveness of Pulmonary Subsolid Nodules on CT Images Using Deep Learning. Frontiers in Oncology, 2021, 11, 700158.	2.8	4
23	Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning. Frontiers in Oncology, 2021, 11, 679764.	2.8	7
24	Dosimetric Comparison, Treatment Efficiency Estimation, and Biological Evaluation of Popular Stereotactic Radiosurgery Options in Treating Single Small Brain Metastasis. Frontiers in Oncology, 2021, 11, 716152.	2.8	4
25	Lymph Node Parameters Predict Adjuvant Chemoradiotherapy Efficacy and Disease-Free Survival in Pathologic N2 Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 736892.	2.8	2
26	Prognostic Value of Inflammatory Biomarkers in Patients With Stage I Lung Adenocarcinoma Treated With Surgical Dissection. Frontiers in Oncology, 2021, 11, 711206.	2.8	18
27	Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Frontiers in Oncology, 2021, 11, 724722.	2.8	3
28	Biomarkers for the prediction of esophageal cancer neoadjuvant chemoradiotherapy response: A systemic review. Critical Reviews in Oncology/Hematology, 2021, 167, 103466.	4.4	6
29	Automatic segmentation of lung tumors on CT images based on a 2D & 3D hybrid convolutional neural network. British Journal of Radiology, 2021, 94, 20210038.	2.2	12
30	Detailed Analysis and Radiomic Prediction of First Progression Sites of First-Line Targeted Therapy for EGFR-Mutant Lung Adenocarcinoma Patients With Systemic Metastasis. Frontiers in Oncology, 2021, 11, 757892.	2.8	0
31	A novel CRT–IMRT–combined (Co–CRIM) planning technique for peripheral lung stereotactic body radiotherapy in pinnacle treatment planning system. Journal of Applied Clinical Medical Physics, 2021, 22, 97-107.	1.9	3
32	Effective Radiotherapy in Tracheobronchial Adenoid Cystic Carcinoma With Positive Surgical Margin. Annals of Thoracic Surgery, 2021, 112, 1585-1592.	1.3	2
33	Lung cancer subtype classification using histopathological images based on weakly supervised multi-instance learning. Physics in Medicine and Biology, 2021, 66, 235013.	3.0	7
34	Timing of thoracic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies. Strahlentherapie Und Onkologie, 2020, 196, 172-181.	2.0	9
35	Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review. Translational Lung Cancer Research, 2020, 9, 2120-2136.	2.8	16
36	Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy. Translational Lung Cancer Research, 2020, 9, 1996-2007.	2.8	11

#	Article	IF	Citations
37	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. Translational Lung Cancer Research, 2020, 9, 2059-2073.	2.8	9
38	On the optimal number of dose-limiting shells in the SBRT auto-planning design for peripheral lung cancer. Journal of Applied Clinical Medical Physics, 2020, 21, 134-142.	1.9	12
39	Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer. Annals of Translational Medicine, 2020, 8, 374-374.	1.7	6
40	Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2020, 21, 534-544.	2.6	10
41	GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence. Frontiers in Oncology, 2020, 10, 824.	2.8	9
42	Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). Radiation Oncology, 2020, 15, 43.	2.7	6
43	Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy. Frontiers in Oncology, 2020, 10, 615167.	2.8	8
44	Clinical significance of age at diagnosis among patients with thymic epithelial tumors: a population-based study. Aging, 2020, 12, 4815-4821.	3.1	7
45	Implementation Strategy of a CNN Model Affects the Performance of CT Assessment of EGFR Mutation Status in Lung Cancer Patients. IEEE Access, 2019, 7, 64583-64591.	4.2	15
46	Postoperative Radiotherapy for Resected Stage IIIA-N2 Non-small-cell Lung Cancer: A Population-Based Time-Trend Study. Lung, 2019, 197, 741-751.	3.3	13
47	Radiation-induced lung injury patterns and the misdiagnosis after SBRT of lung cancer. European Journal of Radiology, 2019, 121, 108708.	2.6	3
48	Expression and prognostic value of FOXP1 in esophageal squamous cell carcinoma. Pathology Research and Practice, 2019, 215, 152645.	2.3	3
49	Predicting the Value of Adjuvant Therapy in Esophageal Squamous Cell Carcinoma by Combining the Total Number of Examined Lymph Nodes with the Positive Lymph Node Ratio. Annals of Surgical Oncology, 2019, 26, 2367-2374.	1.5	21
50	microRNA-messenger RNA regulatory network of esophageal squamous cell carcinoma and the identification of miR-1 as a biomarker of patient survival. Journal of Cellular Biochemistry, 2019, 120, 12259-12272.	2.6	14
51	Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. European Radiology, 2019, 29, 4742-4750.	4.5	121
52	Difference in failure patterns of pT3-4N0-3M0 esophageal cancer treated by surgery vs surgery plus radiotherapy. World Journal of Gastrointestinal Oncology, 2019, 11, 1172-1181.	2.0	6
53	Tissue-based quantitative proteomics to screen and identify the potential biomarkers for early recurrence/metastasis of esophageal squamous cell carcinoma. Cancer Medicine, 2018, 7, 2504-2517.	2.8	22
54	Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients. Pathology Research and Practice, 2018, 214, 1017-1023.	2.3	4

#	Article	IF	Citations
55	Study for reducing lung dose of upper thoracic esophageal cancer radiotherapy by auto-planning: volumetric-modulated arc therapy vs intensity-modulated radiation therapy. Medical Dosimetry, 2018, 43, 243-250.	0.9	15
56	A novel IMRT planning study by using the fixed-jaw method in the treatment of peripheral lung cancer with mediastinal lymph node metastasis. Medical Dosimetry, 2018, 43, 46-54.	0.9	6
57	PS02.033: SIMULTANEOUS INTEGRATED BOOSTING RADIATION DOSE IN UNRESECTABLE THORACIC ESOPHAGEAL CANCER: LONG-TERM OUTCOMES OF A PHASE I/II TRIAL. Ecological Management and Restoration, 2018, 31, 129-129.	0.4	0
58	RA04.05: PREVALENCE OF LYMPH-NODE METASTASIS IN T1B ESOPHAGEAL SQUAMOUS CELL CANCER: IMPLICATIONS FOR ADDITIONAL RADIOTHERAPY DESIGN FOLLOWING ENDOSCOPIC SUBMUCOSAL DISSECTION. Ecological Management and Restoration, 2018, 31, 26-26.	0.4	0
59	The role of prophylactic cranial irradiation in surgically resected combined small cell lung cancer: a retrospective study. Journal of Thoracic Disease, 2018, 10, 3418-3427.	1.4	4
60	Detection of epithelial growth factor receptor (EGFR) mutations on CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks. Journal of Thoracic Disease, 2018, 10, 6624-6635.	1.4	31
61	PS02.036: FAILURE PATTERNS AND LATE TOXICITIES OF CONCURRENT CHEMORADIOTHERAPY FOR CERVICAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA: FROM A PROSPECTIVE OBSERVATIONAL STUDY. Ecological Management and Restoration, 2018, 31, 130-130.	0.4	0
62	The pivotal role of <scp>DNA</scp> methylation in the radio-sensitivity of tumor radiotherapy. Cancer Medicine, 2018, 7, 3812-3819.	2.8	31
63	Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks. British Journal of Radiology, 2018, 91, 20180334.	2.2	18
64	The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy. Scientific Reports, 2018, 8, 9902.	3.3	35
65	The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study. Journal of Translational Medicine, 2018, 16, 100.	4.4	11
66	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	2.8	7
67	Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Radiation Oncology, 2017, 12, 51.	2.7	15
68	Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer. Thoracic Cancer, 2017, 8, 630-633.	1.9	16
69	Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 347-353.	1.1	50
70	Analyses of distribution and dosimetry of brain metastases in small cell lung cancer with relation to the neural stem cell regions: feasibility of sparing the hippocampus in prophylactic cranial irradiation. Radiation Oncology, 2017, 12, 118.	2.7	7
71	A nomogram based on phosphorylated AKT1 for predicting locoregional recurrence in patients with oesophageal squamous cell carcinoma. Journal of Cancer, 2017, 8, 3755-3763.	2.5	3
72	PA-MSHA inhibits proliferation and induces apoptosis in human non-small cell lung cancer cell lines with different genotypes. Molecular Medicine Reports, 2016, 14, 5369-5376.	2.4	6

#	Article	IF	Citations
73	Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer. Oncotarget, 2016, 7, 7227-7240.	1.8	38
74	PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells. Oncotarget, 2016, 7, 49384-49396.	1.8	12
75	Phosphorylated AKT1 is associated with poor prognosis in esophageal squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 95.	8.6	19
76	High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. OncoTargets and Therapy, 2015, 9, 117.	2.0	10
77	High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. Oncotarget, 2015, 6, 18674-18682.	1.8	19
78	Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients With Limited-Stage Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 517-523.	0.8	45
79	Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by 18FDG-PET/CT for esophageal cancer. Radiotherapy and Oncology, 2015, 114, 195-200.	0.6	60
80	The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer, 2015, 15, 348.	2.6	26
81	Tolerance and dose-volume relationship of intrathoracic stomach irradiation after esophagectomy for patients with thoracic esophageal squamous cell carcinoma. Oncotarget, 2015, 6, 32220-32227.	1.8	12
82	Clinical significance of age at diagnosis among young non-small cell lung cancer patients under 40 years old: a population-based study. Oncotarget, 2015, 6, 44963-44970.	1.8	25
83	A prospective phase II clinical study of concurrent chemoradiotherapy for 92 cases cervical esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2015, 33, e15072-e15072.	1.6	0
84	Concurrent chemoradiotherapy with S-1 in elderly patients with esophageal cancer.. Journal of Clinical Oncology, 2015, 33, e15074-e15074.	1.6	0
85	The radiation techniques of tomotherapy & intensity-modulated radiation therapy applied to lung cancer. Translational Lung Cancer Research, 2015, 4, 265-74.	2.8	14
86	Patterns of Failure after Radical Surgery among Patients with Thoracic Esophageal Squamous Cell Carcinoma: Implications for the Clinical Target Volume Design of Postoperative Radiotherapy. PLoS ONE, 2014, 9, e97225.	2.5	67
87	Proposed revision of CT-based cervical and thoracic lymph node levels for esophageal cancer in UICC 7th version. Radiotherapy and Oncology, 2014, 113, 175-181.	0.6	15
88	Patterns of Local-Regional Failure in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Cases: Implications for Postoperative Radiation Therapy Clinical Target Volume Design. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1100-1107.	0.8	39
89	Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma. Strahlentherapie Und Onkologie, 2014, 190, 979-986.	2.0	45
90	Number of Negative Lymph Nodes is Associated with Survival in Thoracic Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy. Annals of Surgical Oncology, 2014, 21, 2857-2863.	1.5	76

#	Article	IF	Citations
91	Sequential Chemoradiotherapy with Accelerated Hypofractionated Radiotherapy Compared to Concurrent Chemoradiotherapy with Standard Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. Technology in Cancer Research and Treatment, 2014, 13, 269-275.	1.9	7
92	Quantitative analysis of tumor shrinkage due to chemotherapy and its implication for radiation treatment planning in limited-stage small-cell lung cancer. Radiation Oncology, 2013, 8, 216.	2.7	9
93	Nodal Skip Metastasis is not a Predictor of Survival in Thoracic Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2013, 20, 3052-3058.	1.5	32
94	Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer?. Radiotherapy and Oncology, 2012, 102, 258-262.	0.6	23
95	A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2011, 98, 304-308.	0.6	36
96	The effect of bioequivalent radiation dose on survival of patients with limited-stage small-cell lung cancer. Radiation Oncology, 2011, 6, 50.	2.7	11
97	Primary carcinomas of the trachea: Natural history, treatment and results. Asia-Pacific Journal of Clinical Oncology, 2005, 1, 41-46.	1.1	1